Omeprazole/antacids swallowable tablet - Salix Pharmaceuticals

Drug Profile

Omeprazole/antacids swallowable tablet - Salix Pharmaceuticals

Alternative Names: Magnesium hydroxide/sodium bicarbonate/omeprazole; Omeprazole/antacids; Sodium bicarbonate/omeprazole/magnesium hydroxide; Zegerid swallowable tablets

Latest Information Update: 04 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Santarus
  • Developer Salix Pharmaceuticals
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Gastric antisecretories; Small molecules
  • Mechanism of Action Antacids; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Gastrointestinal disorders; Heartburn

Most Recent Events

  • 02 Jan 2014 Santarus has been acquired and merged into Salix Pharmaceuticals
  • 31 Oct 2011 Norgine completes a phase III trial in Heartburn in Poland (NCT01493089)
  • 08 Sep 2011 Norgine completes a phase III trial in Heartburn in Bulgaria, Czech Republic, UK and Hungary (EudraCT 2010-022082-10)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top